分子靶向治疗在EGFR突变肺鳞癌中的研究进展  

Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer

作　　者：熊丙万 柯文飞 江文洋[1] Bingwan XIONG;Wenfei KE;Wenyang JIANG(Department of Thoracic Surgery,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院胸外科,武汉430060

出　　处：《中国肺癌杂志》2024年第4期283-290,共8页Chinese Journal of Lung Cancer

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)是我国常见的肿瘤之一,肺鳞癌是NSCLC中除肺腺癌外最常见的组织学亚型。表皮生长因子受体(epidermal growth factor receptor,EGFR)是肺癌的驱动基因之一,相比肺腺癌,肺鳞癌中EGFR的突变率很低。针对EGFR的靶向治疗在肺腺癌中已经取得了重大进展,而在肺鳞癌中的进展相对缓慢。本文对近年EGFR突变肺鳞癌分子靶向治疗的相关研究进行综述,总结出EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)在肺鳞癌中的疗效,旨在为EGFR突变肺鳞癌患者的治疗提供参考。Non-small cell lung cancer(NSCLC)is a prevalent tumour type in our country,with lung squamous carcinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma.Epidermal growth factor receptor(EGFR)is a significant driver gene in lung cancer,and EGFR mutation frequency is considerably lower in lung squamous carcinoma in comparison to lung adenocarcinoma.Although targeted therapy against EGFR has demonstrated significant advancements in lung adenocarcinoma,while progress in lung squamous carcinoma has been relatively sluggish.This paper reviews recent studies on molecular targeted therapy for EGFR-mutated lung squamous carcinoma and summarises the efficacy of EGFR-tyrosine kinase inhibitors(TKIs)in treating squamous carcinoma of the lung,in order to provide a reference for treating patients with EGFR-mutated squamous carcinoma of the lung.

关 键 词：肺肿瘤 表皮生长因子受体 分子靶向治疗 表皮生长因子受体-酪氨激酸酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]